Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Evonik Venture Capital

Founders Ilja Aizenberg Lars Boehnisch

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 35
Average round size
info
The average size of a deal this fund participated in
$11M
Portfolio companies 25
Rounds per year 2.92
Lead investments 12
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Exits 1
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Manufacturing
  • Health Care
  • 3D Printing
  • Advanced Materials
Summary

Evonik Venture Capital appeared to be the VC, which was created in 2012. The main office of represented VC is situated in the Hanau. The fund was located in Europe if to be more exact in Germany. Evonik Venture Capital appeared to be a CVC structure as part of the corporation.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Evonik Venture Capital, startups are often financed by Horizons Ventures, Tau Ventures, SAM Private Equity. The meaningful sponsors for the fund in investment in the same round are Masdar Capital, BASF Venture Capital, VisVires New Protein. In the next rounds fund is usually obtained by Independence Equity, Huron River Ventures, Formation 8.

The fund was created by Lars Boehnisch. The overall number of key employees were 4.

Comparing to the other companies, this Evonik Venture Capital performs on 22 percentage points less the average number of lead investments. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 40 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 5 - 10 millions dollars. The increased amount of exits for fund were in 2018.

We can highlight the next thriving fund investment areas, such as Health Care, Advanced Materials. Among the various public portfolio startups of the fund, we may underline Modern Meadow, FRX Polymers, Biosynthetic Technologies Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Evonik Venture Capital:
Typical Co-investors
Evonik Venture Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Evonik Venture Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Germany
Funds with similar focus located in Germany:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
a>m ventures Memphis, Tennessee, United States
African Rainbow Capital Gauteng, NA - South Africa, South Africa
Bracket Capital Beverly Hills, California, United States
Brightleaf Capital Pennsylvania, Philadelphia, United States
Business Online Public Company Bangkok, Krung Thep, Thailand
CMS Holdings -
Cultural Investment Development Group Beijing, Beijing, China
Fortum Boston, Massachusetts, United States
Galen Investment Advisors California, Oakland, United States
GENIUS Venture Capital Germany, Mecklenburg-Vorpommern, Schwerin
Independence Equity Illinois, Northbrook, United States
Juhua Group China, Hangzhou, Zhejiang
LeanSquare Belgium, Liège, Liege
Qifu Capital Management China, Guangdong, Shenzhen
Ruby Capital Central, Central Region, Singapore
Special Equities Group -
Starter Studio Florida, Orlando, United States
surgical.ai Boston, Massachusetts, United States
U-Start Italy, Lombardy, Milan
VeriSign Bluemont, United States, Virginia

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Velox

Financial Services
FinTech
Manufacturing
Printing
$38M02 Apr 2024 Israel, North District, Israel

Jiangsu Jland Biotech

Biotechnology
Life Science
$20M25 Sep 2023 Nanjing, Jiangsu, China

HPNow

Chemical
$16M19 Sep 2023 Copenhagen, Capital Region of Denmark, Denmark

Allay Therapeutics

Biotechnology
Medical
Therapeutics
13 Dec 2022 Menlo Park, California, United States

In Ovo

Biotechnology
Health Care
Sustainability
Veterinary
$40M01 Mar 2022 Leiden, South Holland, Netherlands

Castor Technologies

3D Printing
Enterprise Software
Information Technology
Software
$3M16 Aug 2021 Tel Aviv-Yafo, Tel Aviv District, Israel

In Ovo

29 Mar 2021 Leiden, Zuid-Holland, The Netherlands

HPNow

Chemical
$6M01 Nov 2020 Copenhagen, Capital Region of Denmark, Denmark

Element Analytics

Analytics
Big Data
Internet of Things
Machine Learning
Predictive Analytics
Software
$18M25 Jun 2020 San Francisco, California, United States
News
Castor Closes $3.5M Seed+ Funding Round

– Castor, an Israeli 3D printing tech company, raised $3.5m in a seed+ funding round.
– The round includes two new investors: Xerox, a global technology company and Spring Ventures, a Tel Aviv based publicly traded company with participation from Evonik Venture Capital, Jeremy Coller, TAU Ventures, and Chartered Group.
– The new investment will be used for product development and marketing.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Evonik Venture Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 35
Average round size 11M
Rounds per year 2.92
Peak activity year 2021
Lead investments 12
Follow on index 0.29
Exits 1
Group Appearance index 0.77

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Velox

Financial Services
FinTech
Manufacturing
Printing
$38M02 Apr 2024 Israel, North District, Israel

Jiangsu Jland Biotech

Biotechnology
Life Science
$20M25 Sep 2023 Nanjing, Jiangsu, China

HPNow

Chemical
$16M19 Sep 2023 Copenhagen, Capital Region of Denmark, Denmark

Allay Therapeutics

Biotechnology
Medical
Therapeutics
13 Dec 2022 Menlo Park, California, United States

In Ovo

Biotechnology
Health Care
Sustainability
Veterinary
$40M01 Mar 2022 Leiden, South Holland, Netherlands

Castor Technologies

3D Printing
Enterprise Software
Information Technology
Software
$3M16 Aug 2021 Tel Aviv-Yafo, Tel Aviv District, Israel

In Ovo

29 Mar 2021 Leiden, Zuid-Holland, The Netherlands

HPNow

Chemical
$6M01 Nov 2020 Copenhagen, Capital Region of Denmark, Denmark

Element Analytics

Analytics
Big Data
Internet of Things
Machine Learning
Predictive Analytics
Software
$18M25 Jun 2020 San Francisco, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: